Regenerx Biopharm In Stock Fundamentals
| RGRXDelisted Stock | USD 0.0009 0.0001 12.50% |
Regenerx Biopharm In fundamentals help investors to digest information that contributes to Regenerx Biopharm's financial success or failures. It also enables traders to predict the movement of Regenerx OTC Stock. The fundamental analysis module provides a way to measure Regenerx Biopharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Regenerx Biopharm otc stock.
Regenerx |
Regenerx Biopharm In OTC Stock Return On Asset Analysis
Regenerx Biopharm's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Regenerx Biopharm Return On Asset | -0.84 |
Most of Regenerx Biopharm's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regenerx Biopharm In is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Regenerx Biopharm In has a Return On Asset of -0.8397. This is 90.4% lower than that of the Biotechnology sector and 96.44% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Regenerx Biopharm Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Regenerx Biopharm's current stock value. Our valuation model uses many indicators to compare Regenerx Biopharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Regenerx Biopharm competition to find correlations between indicators driving Regenerx Biopharm's intrinsic value. More Info.Regenerx Biopharm In is rated second in return on asset category among related companies. It is currently regarded as top stock in operating margin category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Regenerx Biopharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Regenerx Biopharm's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Regenerx Biopharm's earnings, one of the primary drivers of an investment's value.Regenerx Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regenerx Biopharm's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Regenerx Biopharm could also be used in its relative valuation, which is a method of valuing Regenerx Biopharm by comparing valuation metrics of similar companies.Regenerx Biopharm is currently under evaluation in return on asset category among related companies.
Regenerx Fundamentals
| Return On Asset | -0.84 | ||||
| Operating Margin | (19.03) % | ||||
| Current Valuation | 22.91 M | ||||
| Shares Outstanding | 143.55 M | ||||
| Shares Owned By Insiders | 45.99 % | ||||
| Shares Owned By Institutions | 0.01 % | ||||
| Number Of Shares Shorted | 19.19 K | ||||
| Price To Earning | 17.73 X | ||||
| Price To Sales | 261.81 X | ||||
| Revenue | 76.76 K | ||||
| Gross Profit | 70.12 K | ||||
| EBITDA | (1.27 M) | ||||
| Net Income | (1.6 M) | ||||
| Cash And Equivalents | 478.41 K | ||||
| Total Debt | 1.14 M | ||||
| Current Ratio | 1.05 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (990.3 K) | ||||
| Short Ratio | 0.15 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 1.5 | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 20.1 M | ||||
| Total Asset | 1.28 M | ||||
| Retained Earnings | (105.27 M) | ||||
| Working Capital | 806 K | ||||
| Current Asset | 1.19 M | ||||
| Current Liabilities | 382 K | ||||
| Net Asset | 1.28 M |
About Regenerx Biopharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regenerx Biopharm In's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regenerx Biopharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regenerx Biopharm In based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland. REGENERX BIOPHARMACEUTICA operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Regenerx OTC Stock
If you are still planning to invest in Regenerx Biopharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regenerx Biopharm's history and understand the potential risks before investing.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |